Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
Rhea-AI Summary
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, has scheduled a conference call for Tuesday, August 5, 2025, at 5:00 p.m. ET. The call will cover the company's financial performance and corporate updates for Q2 2025, ending June 30, 2025.
Investors can access both the live and replay versions of the webcast through the company's investor relations website. The replay will remain available for three months following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – RARE
On the day this news was published, RARE declined 1.88%, reflecting a mild negative market reaction. This price movement removed approximately $49M from the company's valuation, bringing the market cap to $2.57B at that time.
Data tracked by StockTitan Argus on the day of publication.
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, August 5, 2025, to discuss its financial results and corporate update for the quarter ending June 30, 2025.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
Media
Jess Rowlands
media@ultragenyx.com
FAQ
When is Ultragenyx (NASDAQ: RARE) hosting its Q2 2025 earnings call?
How can investors access Ultragenyx's Q2 2025 earnings call?
How long will the replay of Ultragenyx's Q2 2025 earnings call be available?
What period will Ultragenyx's upcoming earnings report cover?
